ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.266,12
0,57%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,06888
-0,19%
Bitcoin
61.300,01
-0,83%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Galapagos NV (GLPG)

  7. Galapagos NV (GLPG) News

GLPG

Galapagos NV (GLPG)

Galapagos NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GLPG
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202422h01GlobeNewswire Inc.Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024NASDAQ:GLPGGalapagos NV
30/05/202422h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
30/05/202422h01GlobeNewswire Inc.Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsNASDAQ:GLPGGalapagos NV
16/05/202422h28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
16/05/202422h01GlobeNewswire Inc.Galapagos creates new subscription right plansNASDAQ:GLPGGalapagos NV
16/05/202414h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
15/05/202422h01GlobeNewswire Inc.Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.NASDAQ:GLPGGalapagos NV
02/05/202422h01GlobeNewswire Inc.Galapagos reports first quarter 2024 financial results  NASDAQ:GLPGGalapagos NV
30/04/202422h01GlobeNewswire Inc.Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024NASDAQ:GLPGGalapagos NV
04/04/202422h01GlobeNewswire Inc.Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024NASDAQ:GLPGGalapagos NV
28/03/202421h01GlobeNewswire Inc.Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsNASDAQ:GLPGGalapagos NV
26/03/202421h01GlobeNewswire Inc.Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardNASDAQ:GLPGGalapagos NV
23/02/202412h41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
22/02/202422h01GlobeNewswire Inc.Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage PipelineNASDAQ:GLPGGalapagos NV
22/02/202422h01GlobeNewswire Inc.Galapagos announces full year 2023 results and outlook for 2024NASDAQ:GLPGGalapagos NV
16/02/202412h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
15/02/202422h01GlobeNewswire Inc.Galapagos presents at EBMT-EHA annual meeting 2024NASDAQ:GLPGGalapagos NV
14/02/202423h41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLPGGalapagos NV
31/01/202422h01GlobeNewswire Inc.Galapagos completes transaction to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
04/01/202422h44Dow Jones NewsGalapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer DrugNASDAQ:GLPGGalapagos NV
04/01/202422h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
04/01/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
04/01/202422h01GlobeNewswire Inc.Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.NASDAQ:GLPGGalapagos NV
03/01/202422h01GlobeNewswire Inc.Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncologyNASDAQ:GLPGGalapagos NV
03/01/202422h01PR Newswire (US)BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology TargetsNASDAQ:GLPGGalapagos NV
02/01/202407h00GlobeNewswire Inc.Galapagos signs agreement to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
21/12/202322h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
19/12/202322h01GlobeNewswire Inc.Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301NASDAQ:GLPGGalapagos NV
09/12/202318h00GlobeNewswire Inc.Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101NASDAQ:GLPGGalapagos NV
07/12/202322h01GlobeNewswire Inc.Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023NASDAQ:GLPGGalapagos NV
 Showing the most relevant articles for your search:NASDAQ:GLPG

Kürzlich von Ihnen besucht

AMEX
NZW
USOTC
NBEVQ
NewAge (CE)
TSXV
RD
Red Eagle Mining Corporation
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten